Haystack MRD test from Quest Diagnostics - liquid biopsy moves into New York clinics

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-26, 05:47. Details in the imprint.

The Haystack MRD test from Quest Diagnostics starts with a small clear vial of blood and a quiet promise for oncologists, turning circulating tumor DNA into a map of lingering cancer cells. In the lab, it feels more like a targeted radar than a routine assay.

What Haystack MRD does

Haystack MRD is a minimal residual disease test that analyzes circulating tumor DNA in a liquid biopsy to detect remaining or recurring solid tumor cancer after treatment. The assay looks for patient-specific tumor signatures rather than generic markers, giving oncologists a personalized signal of disease activity.

Instead of repeated tissue biopsies, clinicians can track a patient's status with a single tube of blood, which fits naturally into follow-up visits and reduces physical strain. Many oncologists describe the workflow as smoother and more consistent than older MRD protocols that relied on scattered imaging and sporadic lab metrics.

New York approval changes reach

Quest Diagnostics recently secured clearance for the Haystack MRD test from the New York State Department of Health's Clinical Laboratory Evaluation Program, opening use to clinicians across New York. That approval extends what was already available elsewhere in the United States, but New York’s regulatory gate is known as one of the tougher hurdles for advanced lab-developed tests.

For a New York medical oncologist like Dr. Laura Chen, the difference is immediate in everyday practice: she can order Haystack as part of routine follow-up instead of sending samples out of state or juggling interim imaging studies. For cancer centers, it means one more high-sensitivity tool embedded into the existing Quest testing backbone.

How it fits into oncology care

In a typical follow-up visit, a patient might sit in a chair by the window while a phlebotomist slides the needle in, the vial filling with dark red that will be shipped to Quest’s laboratory. Behind the scenes, bioinformatic pipelines match fragments of tumor DNA against the patient’s known mutation profile to reconstruct whether residual cancer remains.

Edward C. Drott, a senior oncology product leader at Quest Diagnostics, has described the company’s MRD focus as a way to bring sophisticated genomic tracking into routine community practice, not just academic centers. The Haystack platform is designed to slot into standard electronic ordering systems and reporting dashboards so oncologists see MRD status alongside other lab values rather than in a separate silo.

Strengths and trade-offs

The test’s key strength is sensitivity: by concentrating on circulating tumor DNA, Haystack MRD can pick up molecular signs of disease before imaging shows visible lesions. For patients in remission, that early signal can trigger a timely change in therapy or closer surveillance, potentially sparing them from blunt, late-stage decisions.

The trade-offs are familiar for high-end diagnostics: sophisticated assays come with higher reimbursement codes and careful interpretation requirements. Oncologists need training to understand how a low-level positive MRD signal should influence treatment, and hospital billing teams must align payer contracts so the test does not surprise patients with uneven coverage.

Platform and service model

Operationally, Haystack MRD runs as a centralized reference lab service rather than an on-premise kit. Hospitals and oncology practices send samples to Quest Diagnostics, which handles sequencing, bioinformatics and reporting. That setup reduces capital expenditure for individual clinics while relying on Quest to maintain quality controls and regulatory oversight.

The service ties into Quest’s broader oncology portfolio, where pathologists and oncologists can combine MRD insights with traditional histopathology, mutation panels and standard bloodwork. For integrated health systems, the attraction lies in using one national lab backbone for logistics and data flows instead of stitching together multiple vendors for different tests.

Pricing and availability

Quest Diagnostics does not advertise a public list price for Haystack MRD, relying instead on negotiated reimbursement rates with insurers and institutional clients. For US readers, the practical reference is that MRD assays sit in a premium tier of oncology diagnostics, often requiring prior authorization under commercial insurance policies.

Availability now covers US states where the company has regulatory clearance, with New York added following the recent approval. For German investors and clinicians, the test would typically be accessed indirectly via US-based treatment partners or clinical trials, as Quest’s core lab footprint and MRD launch remain anchored in the US market.

Stock context for DGX

All told, the Haystack MRD test is part of a broader oncology push that investors track closely when they look at Quest Diagnostics on the New York Stock Exchange. The Quest Diagnostics share price is quoted in US dollars under the ticker DGX, with ISIN US74834L1008, and remains tied to how convincingly the company grows high-value precision testing.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | US74834L1008 | QUEST DIAGNOSTICS | boerse | 69629355 | bgmi